Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Michael L. West is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 4 Finished
-
The FACTs Project: FAbry disease Clinical research and Therapeutics
Medin, J. A. J. A. (PI), Auray-blais, C. C. (CoPI), Casey, R. E. R. E. (CoPI), Clarke, J. T. R. J. T. R. (CoPI), Foley, R. R. (CoPI), Keating, A. A. (CoPI), Khan, A. A. A. A. (CoPI) & West, M. L. (CoPI)
2/1/12 → 1/31/17
Project: Research project
-
The FACTs Project: FAbry disease Clinical research and Therapeutics
Medin, J. A. J. A. (PI), Auray-blais, C. C. (CoPI), Casey, R. E. R. E. (CoPI), Clarke, J. T. R. J. T. R. (CoPI), Foley, R. R. (CoPI), Keating, A. A. (CoPI), Khan, A. A. A. A. (CoPI) & West, M. L. (CoPI)
2/1/12 → 1/31/17
Project: Research project
-
Enzyme replacement therapy for Fabry Disease: A frame work for the integration of rare disease therapeutics into the Canadian Health Care System
Clarke, L. A. (CoPI), Bichet, D. G. (PI), Clarke, J. T. R. J. T. R. (CoPI), Casey, R. E. R. E. (CoPI), Sirrs, S. M. (CoPI) & West, M. L. (CoPI)
4/1/06 → 3/31/09
Project: Research project
-
Enzyme replacement therapy for Fabry Disease: A frame work for the integration of rare disease therapeutics into the Canadian Health Care System
Casey, R. E. R. E. (CoPI), Clarke, L. A. (CoPI), Sirrs, S. M. (CoPI), West, M. L. (CoPI), Bichet, D. G. (PI) & Clarke, J. T. R. (CoPI)
Canadian Institutes of Health Research
4/1/06 → 3/31/09
Project: Research project
-
Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
Hughes, D. A., Aguiar, P., Lidove, O., Nicholls, K., Nowak, A., Thomas, M., Torra, R., Vujkovac, B., West, M. L. & Feriozzi, S., Dec 2022, In: Orphanet Journal of Rare Diseases. 17, 1, 42.Research output: Contribution to journal › Article › peer-review
Open Access7 Citations (Scopus) -
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
on behalf of the FOS Study Group, Aug 2022, In: Journal of Clinical Medicine. 11, 16, 4810.Research output: Contribution to journal › Article › peer-review
Open Access10 Citations (Scopus) -
Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
Beck, M., Ramaswami, U., Hernberg-Ståhl, E., Hughes, D. A., Kampmann, C., Mehta, A. B., Nicholls, K., Niu, D. M., Pintos-Morell, G., Reisin, R., West, M. L., Schenk, J., Anagnostopoulou, C., Botha, J. & Giugliani, R., Dec 2022, In: Orphanet Journal of Rare Diseases. 17, 1, 238.Research output: Contribution to journal › Review article › peer-review
Open Access43 Citations (Scopus) -
Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing
Domm, J. M., Wootton, S. K., Medin, J. A. & West, M. L., Sept 1 2021, In: Molecular Genetics and Metabolism. 134, 1-2, p. 117-131 15 p.Research output: Contribution to journal › Review article › peer-review
32 Citations (Scopus) -
Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products
Sirrs, S. M., Arthus, M. F., Bichet, D. G., Rockman-Greenberg, C., LeMoine, K., Morel, C. F., Lachmann, R., Lynd, L. D., Wasim, S., West, M. L. & Hollak, C., Feb 2021, In: Value in Health. 24, 2, p. 268-273 6 p.Research output: Contribution to journal › Article › peer-review
Open Access10 Citations (Scopus)
Press/Media
-
Findings in Fabry Disease Reported from Charles University and General University Hospital Prague (Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, ...)
11/8/23
1 item of Media coverage
Press/Media: Research
-
Weekly: Anatara Lifesciences (ANR: 2.80c) trading at high volume
6/12/23
1 item of Media coverage
Press/Media: Research
-
Monthly: Anatara Lifesciences (ANR: 2.80c) trails 94% of stocks
4/3/23
1 item of Media coverage
Press/Media: Research
-
Researchers at University Health Network Publish New Study Findings on Gene Therapy (Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease)
3/7/23
1 item of Media coverage
Press/Media: Research
-
CHRISTUS St. Michael to break ground March 28 on emergency center
3/3/23
1 item of Media coverage
Press/Media: Research